INBS vs CUE vs TMO vs ILMN

For growth investors, Cue Biopharma, Inc.

(CUE) is the stronger pick with 195. 7% revenue growth year-over-year, versus -1. 9% for Intelligent Bio Solutions Inc. (INBS). Illumina, Inc. (ILMN) offers the better valuation at 26. 0x trailing P/E (27. 2x forward), making it the more compelling value choice. Analysts rate Thermo Fisher Scientific Inc. (TMO) a "Buy" — based on 42 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Illumina, Inc.

(ILMN) is the cheapest at 26. 0x versus Thermo Fisher Scientific Inc. at 26. 2x. On forward P/E, Thermo Fisher Scientific Inc. is actually cheaper at 18. 7x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Illumina, Inc. wins at 6. 43x versus Thermo Fisher Scientific Inc. 's 8. 86x.

Over the past 5 years, Thermo Fisher Scientific Inc.

(TMO) delivered a total return of +1. 9%, compared to -99. 7% for Intelligent Bio Solutions Inc. (INBS). Over 10 years, the gap is even starker: TMO returned +222. 6% versus INBS's -99. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Thermo Fisher Scientific Inc.

(TMO) is the lower-risk stock at 1. 07β versus Cue Biopharma, Inc. 's 2. 37β — meaning CUE is approximately 120% more volatile than TMO relative to the S&P 500. On balance sheet safety, Intelligent Bio Solutions Inc. (INBS) carries a lower debt/equity ratio of 10% versus 94% for Illumina, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Cue Biopharma, Inc.

(CUE) is pulling ahead at 195. 7% versus -1. 9% for Intelligent Bio Solutions Inc. (INBS). On earnings-per-share growth, the picture is similar: Illumina, Inc. grew EPS 170. 9% year-over-year, compared to 7. 3% for Thermo Fisher Scientific Inc.. Over a 3-year CAGR, CUE leads at 180. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Illumina, Inc.

(ILMN) is the more profitable company, earning 19. 6% net margin versus -346. 2% for Intelligent Bio Solutions Inc. — meaning it keeps 19. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ILMN leads at 19. 9% versus -348. 7% for INBS. At the gross margin level — before operating expenses — CUE leads at 87. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Illumina, Inc. (ILMN) is the more undervalued stock at a PEG of 6. 43x versus Thermo Fisher Scientific Inc. 's 8. 86x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Thermo Fisher Scientific Inc. (TMO) trades at 18. 7x forward P/E versus 27. 2x for Illumina, Inc. — 8. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for TMO: 40. 8% to $654. 67.

In this comparison, TMO (0.

4% yield) pays a dividend. INBS, CUE, ILMN do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Thermo Fisher Scientific Inc.

(TMO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 07), +222. 6% 10Y return). Cue Biopharma, Inc. (CUE) carries a higher beta of 2. 37 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (TMO: +222. 6%, CUE: -90. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: INBS is a small-cap quality compounder stock; CUE is a small-cap high-growth stock; TMO is a mid-cap quality compounder stock; ILMN is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.